91570-99-9Relevant articles and documents
Copper/Selectfluor-System-Catalyzed Dehydration-Oxidation of Tertiary Cycloalcohols: Access to β-Substituted Cyclohex-2-enones, 4-Arylcoumarins, and Biaryls
Ren, Shaobo,Zhang, Jian,Zhang, Jiahui,Wang, Heng,Zhang, Wei,Liu, Yunkui,Liu, Miaochang
supporting information, p. 5381 - 5388 (2015/08/24)
A route to β-substituted cyclohex-2-enones, 4-arylcoumarins, and biaryls has been developed. This approach involves a one-pot Cu0/Selectfluor-catalyzed dehydration-oxidation of tertiary cycloalcohols. Thus, by using 2 equiv. of Selectfluor at 25 C, the dehydration-oxidation of tertiary cyclohexanols and oxabenzocyclohexanols gave β-substituted cyclohex-2-enones and 4-arylcoumarins, respectively; whereas the dehydration-oxidation of tertiary cyclohexanols gave biaryls as the final products by using 2.5 equiv. of Selectfluor at 80 C. A route to β-substituted cyclohex-2-enones, 4-arylcoumarins, and biaryls has been developed. This approach involves a one-pot Cu0/Selectfluor-catalyzed dehydration-oxidation of tertiary cycloalcohols.
Ligand- and base-free Pd(II)-catalyzed controlled switching between oxidative heck and conjugate addition reactions
Walker, Sarah E.,Boehnke, Julian,Glen, Pauline E.,Levey, Steven,Patrick, Lisa,Jordan-Hore, James A.,Lee, Ai-Lan
supporting information, p. 1886 - 1889 (2013/06/04)
A simple change of solvent allows controlled and efficient switching between oxidative Heck and conjugate addition reactions on cyclic Michael acceptor substrates, catalyzed by a cationic Pd(II) catalyst system. Both reactions are ligand- and base-free and tolerant of air and moisture, and the controlled switching sheds light on some of the factors which favor one reaction over the other.
Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
-
Page/Page column 27, (2010/02/14)
Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.